Immune Pharmaceuticals to Take Over Epicept
News Nov 09, 2012
Immune Phamaceuticals Ltd. is taking over EpiCept Corporation in share swap deal. The merged company, Immune Pharmaceuticals Inc., will develop antibody therapeutics and other targeted drugs for the treatment of inflammatory diseases and cancer. The merger is due to close in the first quarter of 2013.
Immune Pharmaceuticals shareholders will own 77.5% of the merged company, and EpiCept shareholders will own 22.5%. The merged company will be headquartered in Herzliya Pituach and in Tarrytown, New York, and will have research laboratories in Rehovot. Immune Pharmaceuticals founder and CEO Dr. Daniel Teper will become the chairman and CEO of the merged company, and Dr. David Sidransky will become vice chairman.
Immune’s lead product candidate, bertilimumab, is a full human monoclonal antibody for the treatment of inflammatory diseases. It is undergoing a Phase II clinical trial for the treatment of ulcerative colitis. The merged company's oncology products will include Immune’s NanomAbs, a new generation of antibody drug conjugates, and EpiCept’s AmiKet, which is undergoing a Phase III clinical trial for the treatment of chemotherapy-induced neuropathic pain and post-herpetic neuralgia.
Teper and EpiCept interim president and CEO Robert Cook said in a statement, "This transaction will create a publicly traded specialty biopharmaceutical company with a portfolio of four clinical-stage drug candidates for the treatment of inflammatory diseases and cancer. Immune's bertilimumab, a first in class monoclonal antibody, is being evaluated clinically to address unmet medical needs in multiple severe disease indications. EpiCept's Amiket has clinical data in over 1,600 patients in various neuropathies, Fast Track designation and Phase III Special Protocol Assistance from the US Food and Drug Administration as well as a defined clinical path through the European Medicines Agency for the treatment of chemotherapy induced neuropathic pain."
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.